ROCHE HOLDING AG ROCHE HOLDING (0QQ6.IL)
| Previous close | 310.40 |
| Open | 312.80 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 309.20 - 313.40 |
| 52-week range | 309.20 - 389.76 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease
Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma PanelThe Elecsys Amyloid Plasma Panel has demonstrated clinical performance and is currently undergoing additional investigation to ensure clinical validationOnce approved, could help healthcare professionals to streamline the journey to diagnosis for more patients Basel, 22 March, 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a collaboration with Eli Lilly and Co
- Business Wire
New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA)
SOUTH SAN FRANCISCO, Calif., March 20, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new long-term data for Evrysdi® (risdiplam) in a broad range of people aged 2-25 years with spinal muscular atrophy (SMA) from the pivotal SUNFISH study. Data confirm increases in motor function were sustained at four years and the overall rate of adverse events continued to decrease over the 48-month period, reinforcing the long-term efficacy and safety of Evrysdi. P
- Globe Newswire
New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
Data from pivotal SUNFISH study showed increases in motor function observed during the first year were maintained through the fourth year, while the overall rate of adverse events continued to decrease Data confirm long-term efficacy and safety profile of Evrysdi in a broad range of people with Type 2 and non‑ambulant Type 3 SMAMore than 8,500 people—from newborns to the over 60s—have been treated with Evrysdi, which is now approved in more than 90 countries worldwide Basel, 20th March 2023 - Ro
